A Phase 1 interventional study of Metformin HCL Tablets, 1000 mg Sandoz and Glucophage 1000 mg in Type 2 Diabetes, sponsored by Sandoz. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Sandoz · Phase 1, Interventional, and Treatment
The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.
Sandoz is the lead sponsor of 136 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Metformin HCL Tablets, 1000 mg
Drug: Metformin HCL Tablets, 1000 mg Sandoz
Glucophage 1000 mg Tablets
Drug: Glucophage 1000 mg
Bioequivalence according to US FDA guidelines
Time frame: 9 days
No study locations are listed for this record.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sandoz